NCT03375502

A Study of MG1111 in Healthy Children

A Phase II/III, Single-blind(Stage 1), Double-blinded(Stage 2), Randomized, Active-controlled, Dose-escalation(Stage 1), Non-inferiority(Stage 2) Study to Evaluate Immunogenicity and Safety of MG1111 in Healthy Children

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 814 (actual)
• Sponsor: Green Cross Corporation · Industry
• Sex: All
• Age: 12 Months – 12 Years
• Healthy volunteers: Accepted

Summary

To assess the safety of MG1111 and to evaluate immunological non-inferiority of MG1111 versus comparator

Conditions

• Healthy Children

Interventions

Type	Name	Description
DRUG	Varicella Vaccine	The subject will receive investigational product or comparator.

Timeline

• Start date: 2016-11-26
• Primary completion: 2019-01-29
• Completion: 2019-07-31
• First posted: 2017-12-18
• Last updated: 2021-05-14

Locations

1 site across 1 country: South Korea